Spontaneous Chylous Ascites After Liver Transplantation Secondary to Everolimus: A Case Report

Transplant Proc. 2020 Mar;52(2):638-640. doi: 10.1016/j.transproceed.2019.10.036. Epub 2020 Feb 3.

Abstract

Chylous ascites (CA) is an uncommon entity with several etiologies. Only a few cases of CA have been reported as a complication after liver transplantation (LT). Most of these cases occurred within 1 month after surgery and typically resulted from traumatic intraoperative injury leading to disruption of lymphatics. Although peripheral lymphedema has been frequently correlated with use of calcineurin inhibitors, associated spontaneous CA has only been reported in a few cases after renal transplantation. We report a case of delayed spontaneous CA after LT caused by the use of the mammalian target of rapamycin (mTOR) inhibitor everolimus. Everolimus was introduced in our patient early after transplantation because of tacrolimus-induced microangiopathy, and years later the patient presented with spontaneous CA. After excluding other causes of CA, everolimus was discontinued, and immunosuppression was maintained by increasing prednisone and continuing mycophenolate mofetil. Additionally, the patient was treated with percutaneous drain placement and began a low-fat, high-protein diet. One month later the patient had complete resolution of symptoms with no recurrence of ascites. To our knowledge, this is the first case of delayed-onset CA caused by everolimus after LT.

Publication types

  • Case Reports

MeSH terms

  • Chylous Ascites / chemically induced*
  • Everolimus / adverse effects*
  • Humans
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / adverse effects*
  • Liver Transplantation*
  • Middle Aged

Substances

  • Immunosuppressive Agents
  • Everolimus